Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment.
But a moat is only valuable if it protects market share and pricing power when competitors come after it. That is exactly what Zoetis is being forced to prove.
DON’T MISS: Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
The moat is built around more than patents
Zoetis has more than 5,500 granted patents and 1,600 pending applications across more than 50 countries. But patents are only part of the advantage. The company also benefits from relationships with veterinarians, a global sales organization, a broad portfolio, and the trust built around established treatments.
That becomes particularly important when patents expire. Zoetis says animal-health products can retain brand loyalty even after patent and regulatory exclusivity ends because veterinarians place a high value on product quality and safety.
The portfolio also creates scale that is difficult for smaller competitors to match. In 2025, the company’s five biggest products and product lines accounted for about 42% of its $9.47 billion in revenue.
That scale gives Zoetis the resources to keep investing in research, marketing and new treatments.
READ ALSO: Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Now competitors are testing it
The problem is that several of Zoetis’ biggest franchises are facing competition at the same time.
Pet owners are becoming more cautious about spending, and that is showing up in fewer visits to veterinary clinics. That would be difficult enough on its own, but Zoetis is also facing tougher competition in a market that is no longer growing as quickly. Rivals are using discounts, rebates, and bundled offers to persuade vets and pet owners to try competing products, including in categories where Zoetis has been the market leader for years.
The numbers show the pressure. Global Companion Animal revenue fell 6% in the second quarter to $1.7 billion, while the company’s key dermatology business fell 16% to $395 million. In the U.S., Companion Animal revenue fell 11%.
Apoquel illustrates the problem particularly well. Management said price has become more important in prescribing decisions, forcing Zoetis to make targeted gross-to-net investments to defend volume and slow share losses. In other words, the company is willing to sacrifice some realized price to protect its position.
That is not necessarily evidence of a broken moat. It is evidence that the moat is being tested.
The pipeline could determine what happens next
Zoetis Inc. is not simply defending its existing products. Management says its pipeline contains more than 12 potential blockbuster products across areas including chronic kidney disease, oncology, cardiology, anxiety and obesity.
That matters because a durable pharmaceutical moat depends partly on replacing aging products with new ones before competitors can weaken the portfolio.
There are also signs that the diversification is helping. Livestock revenue rose 11% organically in Q2, while international Companion Animal revenue increased 5%. That helped offset some of the weakness in the U.S. pet market.
The bear case
The bigger risk is that Zoetis is increasingly fighting for a smaller pool of spending rather than benefiting from a steadily growing market. If fewer pets are being taken to the vet and owners are becoming more conscious of costs, Zoetis may have to give up more on price to protect its market share.
There is another vulnerability: the business is more concentrated than it first appears. Five major products and product lines generated about 42% of revenue in 2025. That means a major competitive threat, loss of exclusivity, or safety problem involving one of those products could have a meaningful impact on the company.
Is the moat starting to crack?
Not yet, but the moat is under pressure. Zoetis still has advantages that would be extremely difficult for a competitor to replicate overnight. Its scale, relationships with veterinarians, research capabilities, and broad portfolio give it several layers of protection.
But the recent weakness in dermatology and other key categories shows that those advantages do not make Zoetis immune to competition. The company is having to work harder to defend volume and, in some cases, accept lower prices to keep customers.
That is probably the most important thing for investors to watch. A moat does not disappear overnight. It usually weakens gradually, as customers become more willing to switch, pricing power fades, and competitors find ways to attack the incumbent. Zoetis is not there yet, but its recent results suggest the moat deserves closer scrutiny than it did a few years ago.
Zoetis is trading at roughly 11.99x forward earnings, versus more than 19x at the end of 2025. The lower valuation suggests the market is already pricing in a significant deterioration in the business.
The question now is whether Zoetis can use its scale, portfolio, and pipeline to turn today’s competitive pressure into a temporary setback rather than a permanent loss of economic power.
Market Sentiment
Hedge fund interest in Zoetis was mixed in Insider Monkey’s latest data. The number of hedge funds holding the stock increased from 57 to 64, while the total value of their positions fell from approximately $2.09 billion to $1.47 billion.
READ NEXT: AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue? OR Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?
This article is originally published at Insider Monkey.
